12‐O‐tetradecanoylphorbol‐13‐acetate (TPA) is an effective cancer therapeutic reagent for myelocytic leukemia patients (Han et al., 1998), and MTURN is TPA‐responsive and may promote both leukemic and normal megakaryocyte differentiation (Sun et al., 2014). Here, MTURN is linked to cancer.